• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Doximity Inc.

    11/7/24 4:38:51 PM ET
    $DOCS
    EDP Services
    Technology
    Get the next $DOCS alert in real time by email
    SC 13G/A 1 DoximityIncDOCS.txt MS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.4)* Doximity, Inc. ----------------------------------------------------- (Name of Issuer) Class A Common Stock ----------------------------------------------------- (Title of Class of Securities) 26622P107 ----------------------------------------------------- (CUSIP Number) September 30, 2024 ----------------------------------------------------- (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No.26622P107 13G Page 2 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley I.R.S. # 36-3145972 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 4,418,266 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 4,837,380 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,863,059 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 3.9% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: HC, CO -------------------------------------------------------------------------------- CUSIP No.26622P107 13G Page 3 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley Investment Management Inc. I.R.S. # 13-3040307 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 3,932,237 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 4,270,340 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,270,340 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 3.4% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: IA, CO -------------------------------------------------------------------------------- CUSIP No.26622P107 13G Page 4 of 8 Pages -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: Doximity, Inc. -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 500 THIRD STREET SAN FRANCISCO CA 94107 UNITED STATES OF AMERICA -------------------------------------------------------------- Item 2. (a) Name of Person Filing: (1) Morgan Stanley (2) Morgan Stanley Investment Management Inc. -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: (1) 1585 Broadway, New York, NY 10036 (2) 1585 Broadway New York, NY 10036 -------------------------------------------------------------- (c) Citizenship: (1) Delaware. (2) Delaware. -------------------------------------------------------------- (d) Title of Class of Securities: Class A Common Stock -------------------------------------------------------------- (e) CUSIP Number: 26622P107 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with Sections 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with sections 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with sections 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No.26622P107 13G Page 5 of 8 Pages -------------------------------------------------------------------------------- Item 4. Ownership as of September 30, 2024.* (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b) Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. (1) As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities. (2) As of the date hereof, Morgan Stanley Investment Management Inc. has ceased to be the beneficial owner of more than five percent of the class of securities. Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit 99.2 Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (1) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release. CUSIP No.26622P107 13G Page 6 of 8 Pages -------------------------------------------------------------------------------- Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 07, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley -------------------------------------------------------------------- MORGAN STANLEY Date: November 07, 2024 Signature: /s/ Deidre A. Downes -------------------------------------------------------------------- Name/Title: Deidre A. Downes/Authorized Signatory, Morgan Stanley Investment Management Inc. -------------------------------------------------------------------- Morgan Stanley Investment Management Inc. EXHIBIT NO. EXHIBITS PAGE ----------- ---------- ---- 99.1 Joint Filing Agreement 7 99.2 Item 7 Information 8 * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.26622P107 13G Page 7 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT --------------------------------------------------- November 07, 2024 --------------------------------------------------- MORGAN STANLEY and Morgan Stanley Investment Management Inc. hereby agree that, unless differentiated, this Schedule 13G is filed on behalf of each of the parties. MORGAN STANLEY BY: /s/ Christopher O'Hara --------------------------------------------------------------------- Christopher O'Hara/Authorized Signatory, Morgan Stanley Morgan Stanley Investment Management Inc. BY: /s/ Deidre A. Downes --------------------------------------------------------------------- Deidre A. Downes/Authorized Signatory, Morgan Stanley Investment Management Inc. * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.26622P107 13G Page 8 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.2 ------------------ ITEM 7 INFORMATION The securities being reported on by Morgan Stanley as a parent holding company are owned, or may be deemed to be beneficially owned, by Morgan Stanley Investment Management Inc., a wholly-owned subsidiary of Morgan Stanley.
    Get the next $DOCS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOCS

    DatePrice TargetRatingAnalyst
    7/9/2025$70.00In-line → Outperform
    Evercore ISI
    6/2/2025$80.00Neutral → Buy
    BTIG Research
    2/7/2025$31.00 → $78.00Neutral → Overweight
    Piper Sandler
    2/7/2025$60.00 → $90.00Market Perform → Outperform
    Leerink Partners
    12/20/2024$55.00Equal-Weight
    Stephens
    12/4/2024$55.00Neutral
    Mizuho
    11/15/2024$58.00Neutral
    Goldman
    11/14/2024$33.00 → $53.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DOCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Doximity Acquires Pathway, a Leader in AI Clinical Reference

    $63M acquisition brings physician AI team and datasets to Doximity's AI suite Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced that it has acquired Pathway Medical Inc., a Montreal-based startup specializing in medical AI and evidence-based clinical reference. Physicians make up half of Pathway's team. Over the past seven years, they've assembled one of the largest structured datasets in medicine—purpose-built for AI—spanning nearly every guideline, drug, and landmark trial across all major specialties. Pathway's model outperforms others in clinical accuracy, recently scoring a record 96% on the U.S. Medical Licensing Examination (

    8/7/25 4:02:00 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity Announces Fiscal 2026 First Quarter Financial Results

    Total revenues of $145.9 million, up 15% year-over-year Operating cash flow of $62.1 million, up 51% year-over-year Free cash flow of $60.1 million, up 52% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 first quarter ended June 30, 2025. "We began our year with strong profit growth and record engagement across our newsfeed, workflow, and AI products," said Jeff Tangney, co-founder and CEO of Doximity. "Our AI suite once again grew the fastest, up 5x year-over-year, while more than 630,000 prescribers used our workflow tools to save time and better serve their patients." Doximity Acquire

    8/7/25 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology

    New Doximity Study Shows Modest Physician Pay Growth Amid Deeper Workforce Strain, Reimbursement Pressures

    Physician pay up 3.7%, but challenges remain: 26% gender wage gap, widespread reimbursement concerns, and deepening financial strain on pediatric care Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today released its 2025 Physician Compensation Report. The findings highlight a healthcare workforce under pressure, with modest compensation growth of 3.7%, a persistent gender pay gap of 26%, and growing concern from pediatric physicians about declining reimbursement. "This year's study reflects a profession that's been under strain for years," said Amit Phull, MD, chief clinical experience officer at Doximity. "Pediatricians and pediatric subspecia

    7/31/25 5:00:00 AM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Leadership Updates

    Live Leadership Updates

    View All

    Parspec Raises $20 Million Series A to Modernize the Construction Supply Chain with AI

    SAN MATEO, Calif., July 8, 2025 /PRNewswire/ -- Parspec, an AI-native software platform that enables wholesale distributors and sales agents to efficiently bid and supply construction products, today announced it has raised $20 million in Series A funding. The round was led by Threshold Ventures (formerly DFJ), with participation from existing venture investors including Innovation Endeavors, Building Ventures, Heartland Ventures, and Hometeam Ventures. Parspec Raises $20 Million Series A to Modernize the Construction Supply Chain with AIThe global construction industry repres

    7/8/25 9:30:00 AM ET
    $BOX
    $DOCS
    $RELY
    Computer Software: Prepackaged Software
    Technology
    EDP Services
    Business Services

    Mendaera Closes $73M Series B Financing to Scale Robotics and AI Across Mainstream Medical Procedures

    With its first-of-its-kind platform, Mendaera is pioneering a new category in medical robotics Mendaera, Inc., a Silicon Valley-based healthcare technology company developing a handheld robotic interventional platform, announced today the close of $73 million in Series B funding led by Threshold Ventures, with participation from investors including Lux Capital, PFM Health Sciences, and Fred Moll (founder of Intuitive Surgical and Auris Health). The financing will further Mendaera's efforts to scale robotics and AI across mainstream medical procedures. The healthcare system is facing an increasing supply and demand crisis, where the ability to consistently deliver high-quality care to pati

    9/26/24 6:05:00 AM ET
    $DOCS
    $RELY
    $LVGO
    EDP Services
    Technology
    Business Services
    Consumer Discretionary

    Doximity Appoints Phoebe Yang to Its Board of Directors

    Experienced director and executive brings health system and cloud expertise SAN FRANCISCO, Aug. 4, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced the appointment of Phoebe L. Yang to its Board of Directors. Ms. Yang has been General Manager at Amazon Web Services, Healthcare, and a member of the board of directors for CommonSpirit Health, one of the largest U.S. health systems. Ms. Yang is a long-time member of the Council on Foreign Relations, and has served as an appointee in two Presidential Administrations. In 2021, she was named one of Modern Healthcare's Top 100 Most Influential People in Healthcare and one

    8/4/22 4:02:00 PM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Bryson Anna covered exercise/tax liability with 5,120 shares, decreasing direct ownership by 1% to 346,925 units (SEC Form 4)

    4 - Doximity, Inc. (0001516513) (Issuer)

    8/15/25 8:24:18 PM ET
    $DOCS
    EDP Services
    Technology

    Chief Executive Officer Tangney Jeffrey covered exercise/tax liability with 7,990 shares, decreasing direct ownership by 0.35% to 2,249,058 units (SEC Form 4)

    4 - Doximity, Inc. (0001516513) (Issuer)

    8/15/25 8:21:54 PM ET
    $DOCS
    EDP Services
    Technology

    Director Benjamin Regina M. converted options into 5,000 shares and sold $315,000 worth of shares (5,000 units at $63.00) (SEC Form 4)

    4 - Doximity, Inc. (0001516513) (Issuer)

    8/11/25 4:02:32 PM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Doximity upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Doximity from In-line to Outperform and set a new price target of $70.00

    7/9/25 8:09:33 AM ET
    $DOCS
    EDP Services
    Technology

    Doximity upgraded by BTIG Research with a new price target

    BTIG Research upgraded Doximity from Neutral to Buy and set a new price target of $80.00

    6/2/25 8:38:31 AM ET
    $DOCS
    EDP Services
    Technology

    Doximity upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Doximity from Neutral to Overweight and set a new price target of $78.00 from $31.00 previously

    2/7/25 9:03:46 AM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    SEC Filings

    View All

    Doximity Inc. filed SEC Form 8-K: Leadership Update

    8-K - Doximity, Inc. (0001516513) (Filer)

    8/15/25 4:01:54 PM ET
    $DOCS
    EDP Services
    Technology

    SEC Form 10-Q filed by Doximity Inc.

    10-Q - Doximity, Inc. (0001516513) (Filer)

    8/7/25 4:11:36 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Doximity, Inc. (0001516513) (Filer)

    8/7/25 4:07:58 PM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Financials

    Live finance-specific insights

    View All

    Doximity Acquires Pathway, a Leader in AI Clinical Reference

    $63M acquisition brings physician AI team and datasets to Doximity's AI suite Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced that it has acquired Pathway Medical Inc., a Montreal-based startup specializing in medical AI and evidence-based clinical reference. Physicians make up half of Pathway's team. Over the past seven years, they've assembled one of the largest structured datasets in medicine—purpose-built for AI—spanning nearly every guideline, drug, and landmark trial across all major specialties. Pathway's model outperforms others in clinical accuracy, recently scoring a record 96% on the U.S. Medical Licensing Examination (

    8/7/25 4:02:00 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity Announces Fiscal 2026 First Quarter Financial Results

    Total revenues of $145.9 million, up 15% year-over-year Operating cash flow of $62.1 million, up 51% year-over-year Free cash flow of $60.1 million, up 52% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 first quarter ended June 30, 2025. "We began our year with strong profit growth and record engagement across our newsfeed, workflow, and AI products," said Jeff Tangney, co-founder and CEO of Doximity. "Our AI suite once again grew the fastest, up 5x year-over-year, while more than 630,000 prescribers used our workflow tools to save time and better serve their patients." Doximity Acquire

    8/7/25 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity to Release Fiscal 2026 First Quarter Results on August 7, 2025

    Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2025 after market close on August 7, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include mor

    7/17/25 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Doximity Inc.

    SC 13G/A - Doximity, Inc. (0001516513) (Subject)

    11/14/24 5:22:01 PM ET
    $DOCS
    EDP Services
    Technology

    SEC Form SC 13G filed by Doximity Inc.

    SC 13G - Doximity, Inc. (0001516513) (Subject)

    11/14/24 11:42:53 AM ET
    $DOCS
    EDP Services
    Technology

    SEC Form SC 13G filed by Doximity Inc.

    SC 13G - Doximity, Inc. (0001516513) (Subject)

    11/12/24 9:55:17 AM ET
    $DOCS
    EDP Services
    Technology